Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buprenorphine transdermal - Mundipharma

Drug Profile

Buprenorphine transdermal - Mundipharma

Alternative Names: BTDS; BuTrans; Butrans; Butrans Transdermal System CIII; Norspan; Norspan Tape; Restive; Sovenor

Latest Information Update: 08 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mundipharma International
  • Developer Grunenthal; Hisamitsu Pharmaceutical; Mundipharma International; Purdue Pharma
  • Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 08 Aug 2019 No development reported - Phase-III for Pain (In adolescents, In children) in USA (Transdermal)
  • 03 Jun 2019 Mundipharma plans a phase III trial for Cancer pain in China (Transdermal) (NCT03967327)
  • 13 May 2019 Mundipharma initiates enrolment in a phase I trial for Pain in China (NCT03975010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top